Tissue angiotensin-II receptor binding after oral TCV-116
Animal study · Adult male Sprague-Dawley rats, 250–290 g; tissue sections assessed by quantitative autoradiography after oral treatment. [1]
One oral dose reduced subsequent radioligand binding in AT1-rich tissues, with partial recovery at 24 h. Binding in AT2-rich adrenal medulla was less affected. This is an ex vivo tissue-binding endpoint after animal exposure, not a direct potency estimate for intact cilexetil or proof of functional central antagonism.
| Endpoint | Reported result | Reference |
|---|---|---|
| Thoracic aortic angiotensin-II receptor binding density | Radioligand binding (dpm/mm²; mean ± SD) Control: 8.7 ± 2.3; 4 h: 5.0 ± 1.0; 24 h: 5.2 ± 0.6; both treated time points p<0.01 vs control. | [1] |
| Adrenal-medullary angiotensin-II receptor binding relative to control | Percentage of control binding 80.7% at 4 h; 88.3% at 24 h (author-reported percentages). | [1] |
Conditions shared by the study groups
- Route
- Oral gavage
- Frequency
- Once
- Treatment course
- Tissue collection at 4 and 24 h
| Group / dose | Comparator | Observed result | Reference |
|---|---|---|---|
| Single oral TCV-116, 1 mg/kg 1 mg/kg | Predose control tissue sections processed in parallel with treated sections; nonspecific binding defined with excess unlabeled [Sar1,Ile8]Ang II. | Aortic binding remained reduced at 24 h; the AT2-rich adrenal medulla showed weaker reduction. | [1] |
- Single oral TCV-116, 1 mg/kg
- Model: Adult male Sprague-Dawley rats; separate terminal tissue collections.
- Reported limits: Vehicle not specified in inspected Methods; Table 1 does not restate its sample count. Methods state four rats at each time point and eight sections per tissue per rat; sections are not independent animals.
Methods and source locations
Compound reported in the paper: Candesartan cilexetil; Compound label in the paper: TCV-116
Applies to oral exposure to the reported prodrug in rats. Does not establish Adooq lot performance or assign the metabolite’s direct receptor affinity to the prodrug.
Methods p. 132; Figures 3–4 pp. 134–135; Table 1 p. 136; Results pp. 136–137; Discussion p. 138
Thoracic aortic angiotensin-II receptor binding density: Quantitative autoradiography using 125I-[Sar1,Ile8]Ang II; nonspecific binding assessed with excess unlabeled ligand. — Table 1, p. 136 (aorta row); Methods p. 132; Figure 3J–L, p. 134
Adrenal-medullary angiotensin-II receptor binding relative to control: Same autoradiographic time-course series; adrenal medulla is described as AT2-predominant. — Results p. 137, adrenal paragraph; Table 1, p. 136 (medulla row); Figure 3G–I, p. 134
Single oral TCV-116, 1 mg/kg · Methods p. 132, Animals and tissue preparation / In vitro quantitative autoradiography; Table 1 p. 136; Results p. 137